Patient characteristics of the whole cohort (N = 2654) and of 50 patients with at least 1 reported pregnancy after alloHCT
| Variable . | All patients (N = 2654) . | Patients with pregnancies (n = 50) . |
|---|---|---|
| Patient age at transplantation, y | ||
| 18-25 | 662 (25%) | 31 (62%) |
| >25-30 | 553 (21%) | 14 (28%) |
| >30-35 | 586 (22%) | 5 (10%) |
| >35-40 | 853 (32%) | — |
| Diagnosis | ||
| Acute leukemia/MDS | 1945 (73%) | 23 (46%) |
| Acquired BM failure, hemoglobinopathies | 180 (7%) | 17 (34%) |
| Other | 529 (20%) | 10 (20%) |
| Karnofsky performance score | ||
| 80-100 | 1909 (72%) | 40 (80%) |
| <80 | 110 (4%) | — |
| Missing | 635 (24%) | 10 (20%) |
| Donor type | ||
| Identical sibling | 709 (27%) | 20 (40%) |
| Alternative donors∗ | 1945 (73%) | 30 (60%) |
| Conditioning† | ||
| Myeloablative | 1354 (51%) | 10 (20%) |
| RIC/NMA | 1300 (49%) | 40 (80%) |
| Cyclophosphamide-based conditioning | ||
| No | 1278 (48%) | 27 (54%) |
| Yes | 1376 (52%) | 23 (46%) |
| TBI | ||
| No | 1228 (46%) | 36 (72%) |
| <8 Gy | 293 (11%) | 8 (15%) |
| ≥8 Gy | 877 (33%) | 4 (8%) |
| Missing | 256 (10%) | 2 (4%) |
| aGVHD until day 100 | ||
| No/grade 1 | 1788 (67%) | 38 (76%) |
| >grade 1 | 742 (28%) | 11 (22%) |
| Missing | 124 (5%) | 1 (2%) |
| cGVHD until year 2‡ | ||
| Yes | 731 (32%) | 15 (30%) |
| No | 888 (39%) | 35 (70%) |
| Missing | 633 (28%) | — |
| Variable . | All patients (N = 2654) . | Patients with pregnancies (n = 50) . |
|---|---|---|
| Patient age at transplantation, y | ||
| 18-25 | 662 (25%) | 31 (62%) |
| >25-30 | 553 (21%) | 14 (28%) |
| >30-35 | 586 (22%) | 5 (10%) |
| >35-40 | 853 (32%) | — |
| Diagnosis | ||
| Acute leukemia/MDS | 1945 (73%) | 23 (46%) |
| Acquired BM failure, hemoglobinopathies | 180 (7%) | 17 (34%) |
| Other | 529 (20%) | 10 (20%) |
| Karnofsky performance score | ||
| 80-100 | 1909 (72%) | 40 (80%) |
| <80 | 110 (4%) | — |
| Missing | 635 (24%) | 10 (20%) |
| Donor type | ||
| Identical sibling | 709 (27%) | 20 (40%) |
| Alternative donors∗ | 1945 (73%) | 30 (60%) |
| Conditioning† | ||
| Myeloablative | 1354 (51%) | 10 (20%) |
| RIC/NMA | 1300 (49%) | 40 (80%) |
| Cyclophosphamide-based conditioning | ||
| No | 1278 (48%) | 27 (54%) |
| Yes | 1376 (52%) | 23 (46%) |
| TBI | ||
| No | 1228 (46%) | 36 (72%) |
| <8 Gy | 293 (11%) | 8 (15%) |
| ≥8 Gy | 877 (33%) | 4 (8%) |
| Missing | 256 (10%) | 2 (4%) |
| aGVHD until day 100 | ||
| No/grade 1 | 1788 (67%) | 38 (76%) |
| >grade 1 | 742 (28%) | 11 (22%) |
| Missing | 124 (5%) | 1 (2%) |
| cGVHD until year 2‡ | ||
| Yes | 731 (32%) | 15 (30%) |
| No | 888 (39%) | 35 (70%) |
| Missing | 633 (28%) | — |